SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Embera NeuroTherapeutics, Inc.' Lead Candidate, EMB-001, Supported by $3.9M Grant from National Institute on Drug Abuse (NIDA)